Industries > Pharma > Epigenetic R&D, Therapies and Diagnostics: Industry and Market Prospects 2014-2024

Epigenetic R&D, Therapies and Diagnostics: Industry and Market Prospects 2014-2024

PUBLISHED: 25 June 2014
PAGES: 254
PRODUCT CODE:

Clear
WOOCS 2.2.1
SKU: N/A Categories: ,

Epigenetics market – new analysis showing you technological trends and sales forecasts
Do you want to find sales potentials of epigenetic technologies, diagnostics and medicines? Now get the latest analysis for that industry. There you explore developments (R&D), results, opportunities, trends and revenue forecasts.

Visiongain’s updated report shows you what’s possible for those drugs, diagnostic tests and related technology. Avoid missing out in data. Instead find progress in that industry and market, discovering expected advances and sales rises. See now how you can gain.

Assess technologies, products and services, benefiting your reputation for technological, medical and commercial insight. Read on, then, to explore that market and see its potential.

Forecasts and other information showing technical, clinical and business prospects
That new study gives you sales predictions to 2024 at overall world market, submarket, product and national level. See what the future holds for that emerging industry. For epigenetics you investigate where demand, opportunity and money lie.

Epigenetic uses hold great potential for diagnosing and treating diseases, including cancer.

There hear what’s possible. And avoid struggles to find information. Besides giving revenue predictions, our analysis shows historical results, growth rates and market shares.

In that work you discover 72 tables, 57 charts and an interview. There help your research, analyses and decisions, also benefiting your influence and staying ahead.

And the following sections explain what our new investigation gives.

World market and its segments – what revenues possible from 2014 to 2024?
What’s the commercial potential of epigenetics? Find in our report overall world revenue to 2024 for those products and technologies.

Also find individual revenue predictions to 2024 for three epigenetic submarkets at world level:
• Therapies
• Technologies for research
• Diagnostics

What’re the secrets of progress? There you assess outlooks for trade expansion, hearing where you could benefit. That work investigates products, uses and rising sales. You find commercial prospects.

That study also predicts and discusses leading epigenetic medicines’ sales potentials.

Revenue predictions for leading drugs and expected therapies
Our study forecasts revenues of top brands – four leading agents and two therapies awaiting launch. There you see individual revenue forecasts to 2024 for these products:
• Vidaza
• Dacogen
• Zolinza
• Istodax

And you gain predictions for these expected treatments:
• Beleodaq
• Faridak

There you explore drugs and years with highest predicted sales. Also you examine competitors. You see what’s happening there, understanding, challenges, trends and outlooks.

For that overall market, the report also shows geographical revenue predictions.

Sales in leading national markets – what outlooks for epigenetics?
Advances in pharmaceuticals, biotechnology and healthcare expand use of epigenetic services and products. See their prospects in developed and developing regions.

Our analyses show you individual revenue forecasts to 2024 for eight national markets and two regions:
• United States (US)
• Japan
• Canada
• Germany, France, UK, Italy and Spain (EU5), also with EU regional prediction
• Brazil, Russia, India and China (BRIC nations, grouped analysis).

There you find countries with highest revenues, demand and potential sales. Explore progress, needs and opportunities, seeing how you can gain. The study explains, helping you stay ahead.

Also how do events, challenges and advances in technology affect that industry and market? Our work shows you, discussing progress, policies and trends.

Strengths, challenges and events – what affects epigenetics?
The report explains issues, events and research and development (R&D) affecting that industry and market from 2014, including these forces:
• Uses for epigenetics in cancer, inherited disorders and neurological diseases
• DNA methlytransferase (DNMT) inhibition
• Histone deacetylase (HDAC) inhibitors
• Drug discovery and development using epigenetics
• Bisulphite screening for DNA methylation.

And you explore these influences and opportunities, among others:
• Chromatin immunoprecipitation (ChIP) for histone modification
• Chemogenic approaches to spatiotemporal regulation of HDAC activity
• Lysine pathways and acetylation-independent mechanisms
• DNMT inhibition and targeting other epigenetic enzymes
• Applications of genomics, proteomics and metabolomics
• Targeting orphan diseases and subpopulations – personalised and stratified medicine.

You explore what progress, trends and prospects mean. And you discover what benefits and restrains companies, affecting commercial performance. So what does the future hold?

Epigenetics – leading companies and 2018 market value
From 2014, applications of epigenetics hold great potential for investments, technological advances and sales. What happens next?

Our new report predicts the world market for those products and technologies will reach $4,279m in 2018, with high further sales growth to 2024.

There you also see what organisations shape that industry:
• Celgene
• Eisai
• Roche
• Janssen-Cilag
• Otsuka Pharmaceuticals
• Merck & Co.

You also assess activities of these firms:
• TopoTarget
• Syndax Pharmaceuticals
• MDxHealth
• Epigenomics
• Life Technologies
• Qiagen, 4SC, EMD Millipore, Orion Genomics, DiscoveRx, EpiTherapeutics and others.

R&D in that industry holds strengths. And from 2014 there will arise many opportunities. From this decade onwards, patients, payers and companies will benefit. See how.

Ways Epigenetic R&D, Therapies and Diagnostics: Industry and Market Prospects 2014-2024 helps
In three main ways our investigation helps your work:
• Revenues to 2024 at overall world level, for 3 submarkets and 6 products – assess outlooks for development, production, marketing and sales
• Forecasts to 2024 for eight national markets and two regions – investigate developed and developing countries for revenues and sales expansion
• Prospects for established competitors, rising companies and new entrants – explore products, R&D, opinions, and outlooks for success.

Knowledge there found nowhere else, benefiting your research, analyses and plans
Our work gives independent analysis. There you receive competitive intelligence found only in that report, seeing where business prospects are most rewarding.

With that investigation you’re less likely to fall behind in data or miss opportunity. Discover there how you can benefit your information searches, analyses and decisions. Also find how you could save time and gain in authority.

Our new study is for everyone assessing the present and future of epigenetics. Your choosing that analysis shows you results, trends, opportunities and sales predictions. So discover potential gains by getting that report here now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Epigenetic R&D, Therapies and Diagnostics: Industry and Market Prospects 2014-2024


Download sample pages

Complete the form below to download your free sample pages for Epigenetic R&D, Therapies and Diagnostics: Industry and Market Prospects 2014-2024


Latest Pharma news

Visiongain Publishes Pharmaceutical Spray Drying Market Report 2021-2031

The rising prevalence of oncological disorders, lung infections, rising demand for customised drugs coupled with new orphan diseases discoveries, are few of the major reasons responsible for development of pharmaceutical spray drying market.

25 October 2021

READ

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

READ

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

READ

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

READ

Categories